Epstein-Barr virus (EBV) and systemic lupus erythematosus (SLE) association in serological studies
DOI:
https://doi.org/10.12775/QS.2025.37.57143Keywords
Epstein-Barr virus, EBV, Systemic lupus erythematosus, SLE, EBV seroprevalence, viral load, autoimmunityAbstract
Over the past 50 years, a substantial body of research revealed an association between Epstein-Barr virus (EBV), and various aspects of EBV infection, with multiple autoimmune diseases. Growing evidence points to EBV as a potential co-factor in systemic lupus erythematosus (SLE) and several mechanisms have been proposed to explain this relationship, however there is as yet no conclusive proof of causality. This literature review constitutes an introduction into the subject and attempts to outline the findings on the EBV-SLE connection, focusing mostly on the evidence provided by serological studies.
References
1. Fairweather DL, Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J Autoimmun. 2009;33(3–4).
2. Bach JF. The hygiene hypothesis in autoimmunity: The role of pathogens and commensals. Vol. 18, Nature Reviews Immunology. 2018.
3. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2009;87(3).
4. Galli L, Chiappini E, de Martino M. Infections and autoimmunity. Pediatr Infect Dis J. 2012 Dec;31(12):1295–7.
5. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity - friends or foes? Vol. 30, Trends in Immunology. 2009.
6. Delogu LG, Deidda S, Delitala G, Manetti R. Infectious diseases and autoimmunity. Vol. 5, Journal of Infection in Developing Countries. 2011.
7. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. Vol. 108, Journal of Clinical Investigation. 2001.
8. Khasnis AA, Schoen RT, Calabrese LH. Emerging Viral Infections in Rheumatic Diseases. Semin Arthritis Rheum. 2011;41(2).
9. Perl A. Mechanisms of viral pathogenesis in rheumatic disease. Ann Rheum Dis. 1999;58(8).
10. Amital H, Govoni M, Maya R, Meroni PL, Ori B, Shoenfeld Y, et al. Role of infectious agents in systemic rheumatic diseases. Vol. 26, Clinical and Experimental Rheumatology. 2008.
11. McClain MT, Harley JB, James JA. The role of Epstein-Barr virus in systemic lupus erythematosus. Vol. 6, Frontiers in bioscience : a journal and virtual library. 2001.
12. Hanlon P, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther. 2014;16(1).
13. Houen G, Trier NH. Epstein-Barr Virus and Systemic Autoimmune Diseases. Vol. 11, Frontiers in Immunology. 2021.
14. Dong L, Umehara H, Zhong J. Editorial: Rheumatic Diseases and Infection. Vol. 9, Frontiers in Medicine. 2022.
15. Maślińska M. The role of Epstein–Barr virus infection in primary Sjögren’s syndrome. Vol. 31, Current Opinion in Rheumatology. 2019.
16. James JA, Scofield RH, Harley JB. Lupus humoral autoimmunity after short peptide immunization. In: Annals of the New York Academy of Sciences. 1997.
17. Li ZX, Zeng S, Wu HX, Zhou Y. The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis. Clin Exp Med. 2019 Feb;19(1):23–36.
18. Gordon C. Long-term complications of systemic lupus erythematosus. Vol. 41, Rheumatology. 2002.
19. Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus A systematic review and meta-analysis. Vol. 95, Medicine (United States). 2016.
20. Han L, Zhang Y, Wang Q, Xin M, Yang K, Lei K, et al. Epstein–Barr virus infection and type I interferon signature in patients with systemic lupus erythematosus. Lupus. 2018;27(6).
21. Afrasiabi A, Keane JT, Ong LTC, Alinejad-Rokny H, Fewings NL, Booth DR, et al. Genetic and transcriptomic analyses support a switch to lytic phase in Epstein Barr virus infection as an important driver in developing Systemic Lupus Erythematosus. J Autoimmun. 2022;127.
22. Bastidas Goyes AR, Mora C, Arsanios DM, Orduz K. Systemic lupus erythematosus, a disease conditioned by the environment. Vol. 28, Revista Colombiana de Reumatologia. 2021.
23. Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, et al. Spectrum of Epstein-Barr virus-related diseases: A pictorial review. Vol. 27, Japanese Journal of Radiology. 2009.
24. Hiraki A, Fujii N, Masuda K, Ikeda K, Tanimoto M. Genetics of Epstein-Barr virus infection. Biomedicine and Pharmacotherapy. 2001;55(7).
25. Young LS, Rickinson AB. Epstein-Barr virus: 40 Years on. Vol. 4, Nature Reviews Cancer. 2004.
26. Macsween KF, Crawford DH. Epstein-Barr virus - Recent advances. Vol. 3, Lancet Infectious Diseases. 2003.
27. Crawford DH. Biology and disease associations of Epstein-Barr virus. Vol. 356, Philosophical Transactions of the Royal Society B: Biological Sciences. 2001.
28. Kieff E, Dambaugh T, Heller M, King W, Cheung A, Van Santen V, et al. The biology and chemistry of epstein-barr virus. Journal of Infectious Diseases. 1982;146(4).
29. Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: A review. Vol. 53, Journal of Clinical Pathology. 2000.
30. Thorley-Lawson DA. EBV persistence-introducing the virus. In: Epstein Barr Virus. 2015.
31. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Vol. 61, Annals of Neurology. 2007.
32. Rubicz R, Yolken R, Drigalenko E, Carless MA, Dyer TD, Bauman L, et al. A Genome-Wide Integrative Genomic Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1). PLoS Genet. 2013;9(1).
33. Straus SE, Cohen JI, Tosato G, Meier J. Epstein-Barr virus infections: Biology, pathogenesis, and management. In: Annals of Internal Medicine. 1993.
34. Draborg AH, Duus K, Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:370516.
35. Betterle C, Zanchetta R. The immunofluorescence techniques in the diagnosis of endocrine autoimmune diseases. Vol. 3, Autoimmunity Highlights. 2012.
36. Dalldorf G, Carvalho RPS, Jamra M, Erlich D, Marigo C. The Lymphomas of Brazilian Children. JAMA: The Journal of the American Medical Association. 1969;208(8).
37. Evans AS. The spectrum of infections with epstein-barr virus: A hypothesis. Vol. 124, Journal of Infectious Diseases. 1971.
38. Evans AlfredS, Rothfield NaomiF, Niederman JamesC. RAISED ANTIBODY TITRES TO E.B. VIRUS IN SYSTEMIC LUPUS ERYTHEMATOSUS. The Lancet. 1971 Jan;297(7691):167–8.
39. Rothfield NF, Evans AS, Niederman JC. Clinical and laboratory aspects of raised virus antibody titres in systemic lupus erythematosus. Ann Rheum Dis. 1973;32(3).
40. Evans AS, Rothfield NF. E.B. VIRUS AND OTHER VIRAL ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS. Vol. 301, The Lancet. 1973.
41. Klippel JH, Decker JL, Grimley PM, Evans AS, Rothfield NF. EPSTEIN-BARR VIRUS ANTIBODY AND LYMPHOCYTE TUBULORETICULAR STRUCTURES IN SYSTEMIC LUPUS ERYTHEMATOSUS. The Lancet. 1973;302(7837).
42. Stevens DA, Stevens MB, Newell GR, Levine PH, Waggoner DE. Epstein-Barr Virus (Herpes-Type Virus) Antibodies in Connective Tissue Diseases. Arch Intern Med. 1972;130(1).
43. Phillips PE, Hirshaut Y. Epstein‐barr virus antibody levels in systemic lupus erythematosus. Arthritis Rheum. 1973;16(1).
44. Gergely L, Czeglédy J, Váczi L, Gönczöl É, Szegedi G, Berényi E. E.B.V. ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS. Vol. 301, The Lancet. 1973.
45. Evans AS. Commentary. EB virus, infectious mononucleosis, and cancer: the closing of the web. Yale J Biol Med. 1974;47(2):113–22.
46. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJA, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. Journal of Clinical Investigation. 1997;100(12).
47. Stancek D, Rovensky J. Enhancement of Epstein-Barr virus antibody production in systemic lupus erythematosus patients. Acta Virol. 1979;23(2).
48. Catalano MA, Carson DA, Slovin SF, Richman DD, Vaughan JH. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proc Natl Acad Sci U S A. 1979;76(11).
49. Kitagawa H, Iho S, Yokochi T, Hoshino T. Detection of antibodies to the Epstein-Barr virus nuclear antigens in the sera from patients with systemic lupus erythematosus. Immunol Lett. 1988;17(3).
50. Yokochi T, Yanagawa A, Kimura Y, Mizushima Y. High titer of antibody to the Epstein-Barr virus membrane antigen in sera from patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 1989 Aug;16(8):1029–32.
51. Sculley DG, Sculley TB, Pope JH. Reactions of sera from patients with rheumatoid arthritis, systemic lupus erythematosus and infectious mononucleosis to Epstein-Barr virus-induced polypeptides. Journal of General Virology. 1986;67(10).
52. Ngou J, Segondy M, Seigneurin J ‐M, Graafland H. Antibody responses against polypeptide components of Epstein‐Barr virus‐induced early diffuse antigen in patients with connective tissue diseases. J Med Virol. 1990;32(1).
53. Dror Y, Blachar Y, Cohen P, Livni N, Rosenmann E, Ashkenazi A. Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. American Journal of Kidney Diseases. 1998;32(5).
54. Bhimma R, Adhikari M, Coovadia HM. Epstein-Barr virus-induced systemic lupus erythematosus. S Afr Med J. 1995 Sep;85(9):899–900.
55. James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 2001;44(5).
56. Incaprera M, Rindi L, Bazzichi A, Garzelli C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol. 1998;16(3).
57. Jog NR, James JA. Epstein Barr Virus and Autoimmune Responses in Systemic Lupus Erythematosus. Vol. 11, Frontiers in Immunology. 2021.
58. Turner BRH, Mellor C, McElroy C, Bowen N, Gu W, Knill C, et al. Non-ubiquitous expression of core spliceosomal protein SmB/B′ in chick and mouse embryos. Developmental Dynamics. 2023;252(2).
59. Poole BD, Gross T, Maier S, Harley JB, James JA. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun. 2008;31(4).
60. Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet. 2018;50(5).
61. Tsai YT, Kao YF, Chiang BL, Hsieh KH. Detection of epstein-barr virus and cytomegalovirus genome in white blood cells from patients with juvenile rheumatoid arthritis and childhood systemic lupus erythematosus. Int Arch Allergy Immunol. 1995;106(3).
62. Lau CS, Yuen KY, Chan KH, Wong RW. Lack of evidence of active lytic replication of Epstein-Barr and cytomegaloviruses in patients with systemic lupus erythematosus. Chin Med J (Engl). 1998 Jul;111(7):660–5.
63. Katz BZ, Salimi B, Kim S, Nsiah-Kumi P, Wagner-Weiner L. Epstein-Barr virus burden in adolescents with systemic lupus erythematosus. Pediatr Infect Dis J. 2001 Feb;20(2):148–53.
64. Kang I, Quan T, Nolasco H, Park SH, Hong MS, Crouch J, et al. Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus Erythematosus. The Journal of Immunology. 2004;172(2).
65. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein–Barr virus load in blood. Arthritis Res Ther. 2004;6(4).
66. Strauch B, Andrews LL, Siegel N, Miller G. Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet. 1974 Feb 16;1(7851):234–7.
67. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and Systemic Lupus Erythematosus: A New Perspective. The Journal of Immunology. 2005;174(11).
68. Yu SF, Wu HC, Tsai WC, Yen JH, Chiang W, Yuo CY, et al. Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med Microbiol Immunol. 2005;194(3).
69. Lu JJY, Chen DY, Hsieh CW, Lan JL, Lin FJ, Lin SH. Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan. Lupus. 2007;16(3).
70. Larsen M, Sauce D, Deback C, Arnaud L, Mathian A, Miyara M, et al. Exhausted cytotoxic control of epstein-barr virus in human lupus. PLoS Pathog. 2011;7(10).
71. Draborg AH, Jacobsen S, Westergaard M, Mortensen S, Larsen JL, Houen G, et al. Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients. Lupus Sci Med. 2014;1(1).
72. Berner BR, Tary-Lehmann M, Yonkers NL, Askari AD, Lehmann P V., Anthony DD. Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol. 2005;235(1).
73. Draborg AH, Sandhu N, Larsen N, Lisander Larsen J, Jacobsen S, Houen G. Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients. J Immunol Res. 2016;2016.
74. Draborg AH, Lydolph MC, Westergaard M, Larsen SO, Nielsen CT, Duus K, et al. Erratum: Elevated concentrations of serum immunoglobulin free light chains in systemic lupus erythematosus patients in relation to disease activity, inflammatory status, B cell activity and Epstein-Barr virus antibodies (PLoS ONE (2015) 10:9 (e0138753) DOI: 10.1371/journal.pone.0138753). Vol. 11, PLoS ONE. 2016.
75. Piroozmand A, Kashani HH, Zamani B. Correlation between Epstein-Barr virus infection and disease activity of systemic lupus erythematosus: A cross-sectional study. Asian Pacific Journal of Cancer Prevention. 2017;18(2).
76. Broccolo F, Drago F, Cassina G, Fava A, Fusetti L, Matteoli B, et al. Selective reactivation of human herpesvirus 6 in patients with autoimmune connective tissue diseases. J Med Virol. 2013;85(11).
77. Banko A, Cirkovic A, Miskovic R, Jeremic I, Grk M, Basaric M, et al. Epstein-Barr virus infection as potential indicator of the occurrence and clinical presentation of systemic lupus erythematosus. Front Immunol. 2023;14.
78. Ming B, Bai M, Cai S, Wang B, Zhong J, Dong L. Clinical characteristics of SLE patients infected with Epstein-Barr virus and potential associated risk factors. Clin Rheumatol. 2023;42(1).
79. Chen X, Li H, Wu C, Zhang Y. Epstein‒Barr virus and human herpesvirus 6 infection in patients with systemic lupus erythematosus. Virol J. 2023;20(1).
80. Das P, Minz RW, Saikia B, Sharma A, Anand S, Singh H, et al. Association of Human Leucocyte Antigen Class II, with viral load and immune response to Epstein–Barr virus in adult and pediatric Systemic lupus erythematosus patients. Lupus. 2022;31(9).
81. Aygun D, Kuskucu MA, Sahin S, Adrovic A, Barut K, Yıldız M, et al. Epstein–Barr virus, cytomegalovirus and BK polyomavirus burden in juvenile systemic lupus erythematosus: correlation with clinical and laboratory indices of disease activity. Lupus. 2020;29(10).
82. Miskovic R, Cirkovic A, Miljanovic D, Jeremic I, Grk M, Basaric M, et al. Epstein–Barr Virus Reactivation as a New Predictor of Achieving Remission or Lupus Low Disease Activity State in Patients with Systemic Lupus Erythematosus with Cutaneous Involvement. Int J Mol Sci. 2023;24(7).
83. Truszewska A, Wirkowska A, Gala K, Truszewski P, Krzemień-Ojak Ł, Mucha K, et al. EBV load is associated with cfDNA fragmentation and renal damage in SLE patients. Lupus. 2021;30(8).
84. Yokochi T, Yanagawa A, Kimura Y, Mizushima Y. High titer of antibody to the Epstein-Barr virus membrane antigen in sera from patients with rheumatoid arthritis and systemic lupus erythematosus. Journal of Rheumatology. 1989;16(8).
85. Westgeest AAA, Van Loon AM, Van Der Logt JTM, Van de Putte LBA, Boerbooms AMT. Antiperinuclear factor, a rheumatoid arthritis specific autoantibody: Its relation to Epstein-Barr virus. Journal of Rheumatology. 1989;16(5).
86. Marchini B, Dolcher MP, Sabbatini A, Klein G, Migliorini P. Immune response to different sequences of the EBNA I molecule in Epstein- Barr virus-related disorders and in autoimmune diseases. J Autoimmun. 1994;7(2).
87. Ngou J, Segondy M. Immunoblotting reactivity of sera from patients with autoimmune connective tissue diseases against Epstein-Barr nuclear antigen (EBNA) polypeptides. Serodiagnosis and Immunotherapy in Infectious Disease. 1996;8(2).
88. NEWKIRK MM, SHIROKY JB, JOHNSON N, DANOFF D, ISENBERG DA, SHUSTIK C, et al. RHEUMATIC DISEASE PATIENTS, PRONE TO SJÖGREN’S SYNDROME AND/OR LYMPHOMA, MOUNT AN ANTIBODY RESPONSE TO BHRF1, THE EPSTEIN-BARR VIRAL HOMOLOGUE OF BCL-2. Rheumatology. 1996 Nov;35(11):1075–81.
89. Zhang X, Li B, Liu Y, Jiang M. Clinical study on antibodies against EBV in sera of patients with rheumatoid arthritis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1999;21(1).
90. Stratta P, Canavese C, Ciccone G, Santi S, Quaglia M, Ghisetti V, et al. Correlation between cytomegalovirus infection and Raynaud’s phenomenon in lupus nephritis. Nephron. 1999;82(2).
91. Huggins ML, Todd I, Powell RJ. Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatol Int. 2005 Apr;25(3):183–7.
92. Chen CJ, Lin KH, Lin SC, Tsai WC, Yen JH, Chang SJ, et al. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: Case control studies. Journal of Rheumatology. 2005;32(1).
93. Parks CG, Cooper GS, Hudson LL, Dooley MA, Treadwell EL, St.Clair EW, et al. Association of Epstein-Barr virus with systemic lupus erythematosus: Effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum. 2005;52(4).
94. Faheem M, Naseer MI, Rasool M, Chaudhary AG, Kumosani TA, Ilyas AM, et al. Molecular genetics of human primary microcephaly: An overview. Vol. 8, BMC Medical Genomics. 2015.
95. Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M, et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. In: Annals of the New York Academy of Sciences. 2009.
96. Tazi I, Fehri S, Elghrari K, Ouazzani T, Benchemsi N. [Systemic lupus erythematosus and Epstein-Barr virus]. East Mediterr Health J. 2009;15(3):701–8.
97. Berkun Y, Zandman-Goddard G, Barzilai O, Boaz M, Sherer Y, Larida B, et al. Infectious antibodies in systemic lupus erythematosus patients. Lupus. 2009;18(13).
98. Esen BA, YIlmaz G, Uzun S, Özdamar M, Aksözek A, KamalI S, et al. Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: A controlled study. Rheumatol Int. 2012;32(1).
99. Chen DY, Chen YM, Lan JL, Chen HH, Hsieh CW, Wey SJ, et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: The Epstein-Barr virus connection? Journal of Clinical Virology. 2010;49(4).
100. Sun Y, Sun S, Li W, Li B, Li J. Prevalence of human herpesvirus 8 infection in systemic lupus erythematosus. Virol J. 2011;8.
101. Us T, Cetin E, Kaşifoǧlu N, Kaşifoǧlu T, Akgün Y. [Investigation of Epstein-Barr virus and herpes simplex virus markers by serological and molecular methods in patients with rheumatoid arthritis and systemic lupus erythematosus]. Mikrobiyol Bul. 2011;45(4).
102. Draborg AH, Jørgensen JM, Müller H, Nielsen CT, Jacobsen S, Iversen L V, et al. Epstein-Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients. Scand J Rheumatol. 2012 Aug;41(4):280–9.
103. Csuka D, Simon D, Hóbor R, Uray K, Prohászka Z, Bánlaki Z, et al. Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35-58 or aa398-404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis. Clin Exp Immunol. 2013;171(3).
104. Rasmussen N, Draborg A, Nielsen C, Jacobsen S, Houen G. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol. 2015;44(2).
105. Vista ES, Weisman MH, Ishimori ML, Chen H, Bourn RL, Bruner BF, et al. Strong viral associations with SLE among Filipinos. Lupus Sci Med. 2017;4(1).
106. Chougule D, Nadkar M, Rajadhyaksha A, Pandit-Shende P, Surve P, Dawkar N, et al. Association of clinical and serological parameters of systemic lupus erythematosus patients with Epstein-Barr virus antibody profile. J Med Virol. 2018;90(3).
107. Sternbæk L, Draborg AH, Østerlund MT, Iversen L V., Troelsen L, Theander E, et al. Increased antibody levels to stage-specific Epstein–Barr virus antigens in systemic autoimmune diseases reveal a common pathology. Scand J Clin Lab Invest. 2019;79(1–2).
108. Lemus YB, Martínez GA, Lugo LP, Escorcia LG, Peñata EZ, Llanos NS, et al. Gene profiling of Epstein-Barr Virus and human endogenous retrovirus in peripheral blood mononuclear cells of SLE patients: immune response implications. Sci Rep. 2024 Aug 30;14(1):20236.
109. Mišković R, Rašković S, Banko A. The role of Epstein-Barr virus in systemic lupus erythematosus. Medicinski podmladak. 2023;74(3).
110. Robinson WH, Younis S, Love ZZ, Steinman L, Lanz T V. Epstein-Barr virus as a potentiator of autoimmune diseases. Nat Rev Rheumatol. 2024 Nov;20(11):729–40.
111. Laurynenka V, Ding L, Kaufman KM, James JA, Harley JB. A High Prevalence of Anti-EBNA1 Heteroantibodies in Systemic Lupus Erythematosus (SLE) Supports Anti-EBNA1 as an Origin for SLE Autoantibodies. Front Immunol. 2022;13.
112. Quaglia M, Merlotti G, De Andrea M, Borgogna C, Cantaluppi V. Review viral infections and systemic lupus erythematosus: New players in an old story. Vol. 13, Viruses. 2021.
113. Lossius A, Johansen JN, Torkildsen Ø, Vartdal F, Holmoy T. Epstein-barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis-association and causation. Vol. 4, Viruses. 2012.
114. Draborg AH, Duus K, Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol. 2013;2013:535738.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Witold Czyż, Marta Chuncia-Ilczeko, Michalina Wójcikiewicz, Filip Arczewski, Karol Dziedzic, Julia Kulbacka, Maciej Wojszczyk, Damian Zys, Piotr Pasek, Julia Ryniecka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 95
Number of citations: 0
